Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Trial Profile

A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciforadenant (Primary) ; CPI-006 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions
  • Sponsors Corvus Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2019 According to a Corvus Pharmaceuticals media release, the company will host an investor and analyst reception to discuss data presented at SITC 2019
    • 08 Nov 2019 According to a Corvus Pharmaceuticals media release, Based on the data to-date from the dose-escalation portion of the study, the Company has selected a CPI-006 dose of 18 mg/kg every three weeks for continued expansion in the monotherapy arm.
    • 08 Nov 2019 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top